Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 02, 2023

Safety Profile of Evobrutinib in Patients With MS, Rheumatoid Arthritis, or Systemic Lupus Erythematosus

Journal of Neurology, Neurosurgery, and Psychiatry


Additional Info

Journal of Neurology, Neurosurgery, and Psychiatry
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
J. Neurol. Neurosurg. Psychiatr. 2023 Jan 01;94(1)1-9, X Montalban, D Wallace, MC Genovese, D Tomic, D Parsons-Rich, C Le Bolay, AH Kao, H Guehring

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading